Viewing Study NCT00068094


Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2025-12-26 @ 3:19 AM
Study NCT ID: NCT00068094
Status: TERMINATED
Last Update Posted: 2006-08-18
First Post: 2003-09-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
Sponsor: National Center for Complementary and Integrative Health (NCCIH)
Organization:

Study Overview

Official Title: The Effect of a Probiotic on Hepatic Steatosis
Status: TERMINATED
Status Verified Date: 2006-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.
Detailed Description: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and is also common in diabetics; unfortunately, research on NAFLD has been limited. Safe, inexpensive, and well-tolerated treatments for NAFLD are needed. Recent studies indicate that probiotics help to improve fat breakdown in mice. This study will evaluate the efficacy of probiotic therapy to reduce fat accumulation in the livers of people with NAFLD and diabetes.

Participants in this study will be randomly assigned to receive either a probiotic-containing mixture or placebo once daily for 6 months. Blood tests, and magnetic resonance spectroscopy will be used to assess participants at study start and at study completion.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: